Real-World Lenvatinib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis
ConclusionsIn clinical real-life practice, lenvatinib illustrated promising survival benefits and acceptable safety for patients with unresectable HCC, while reducing the risk of progression disease compared with sorafenib. Additionally, lack of approved post-lenvatinib systemic therapies is a serious issue in the real world.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
More News: Bilirubin | Cancer & Oncology | Carcinoma | Chemotherapy | Clinical Trials | Hepatocellular Carcinoma | Liver Cancer | Study